Not for medicinal use
Participants who completed VESPER-1 were eligible to enroll in an exploratory open-label extension that evaluated higher weekly dosing (1.6 mg, 2.4 mg) and less frequent dosing (every other week and monthly)
Understanding the potential indirect mechanismsincluding rapid weight loss, electrolyte disturbances, and dehydrationcan help patients and clinicians manage these symptoms effectively
It can be used for neuralgia, rheumatism of the soft tissues, arthritic conditions, carpal tunnel syndrome, sciatica, herniated/bulging disc pain
Li J, Dong XQ, Cao LH, Zhang ZQ, Zhao WF, Shang QH, Zhang DZ, Ma AL, Xie Q, Gui HL, Zhang G, Liu YX, Shang J, Xie SB, Liu YQ, Zhang C, Wang GQ, Zhao H, China HepB Related Fibrosis Assessment Research Group